Early-onset pancreatic cancer : a population-based study using the SEER registry

Published on Aug 1, 2019in Langenbeck's Archives of Surgery2.093
· DOI :10.1007/s00423-019-01810-0
Daniel Ansari19
Estimated H-index: 19
Carl Althini1
Estimated H-index: 1
(Lund University)
+ 1 AuthorsRoland Andersson54
Estimated H-index: 54
Background Early-onset pancreatic cancer (< 50 years, EOPC) is uncommon and limited data exist on clinical presentation and long-term survival. The aim of this study was to compare outcomes between patients with EOPC and those with later-onset pancreatic cancer (≥ 50 years, LOPC) using a large population-based cohort.
  • References (26)
  • Citations (0)
📖 Papers frequently viewed together
15 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 47
#2Kimberly D. Miller (ACS: American Cancer Society)H-Index: 18
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 106
view all 3 authors...
990 CitationsSource
#1Chara Ntala (QMUL: Queen Mary University of London)H-Index: 1
#2Silvana Debernardi (QMUL: Queen Mary University of London)H-Index: 13
Last. Tatjana Crnogorac-Jurcevic (QMUL: Queen Mary University of London)H-Index: 30
view all 4 authors...
Background Early onset pancreatic cancer (EOPC), i.e. pancreatic ductal adenocarcinoma (PDAC) occurring in patients below 50 years of age, is rare and there is limited information regarding risk factors, molecular basis and outcome. This study aimed to determine the demographic and clinicopathological features and survival figures for EOPC.
1 CitationsSource
#1Vanessa L. Gordon-Dseagu (NIH: National Institutes of Health)H-Index: 2
#2Susan S. Devesa (NIH: National Institutes of Health)H-Index: 77
Last. Rachael Z. Stolzenberg-Solomon (NIH: National Institutes of Health)H-Index: 13
view all 4 authors...
13 CitationsSource
#1Anne Michelle Noone (NIH: National Institutes of Health)H-Index: 3
#2Jennifer L. LundH-Index: 16
Last. Joan L. Warren (NIH: National Institutes of Health)H-Index: 51
view all 7 authors...
Background: The population-based Surveillance, Epidemiology, and End Results (SEER) registries collect information on first-course treatment, including surgery, chemotherapy, radiation therapy, and hormone therapy. However, the SEER program does not release data on chemotherapy or hormone therapy due to uncertainties regarding data completeness. Activities are ongoing to investigate the opportunity to supplement SEER treatment data with other data sources.
108 CitationsSource
#1Alexander P. Stark (UCLA: University of California, Los Angeles)H-Index: 6
#2Greg D. Sacks (UCLA: University of California, Los Angeles)H-Index: 13
Last. O. Joe Hines (UCLA: University of California, Los Angeles)H-Index: 53
view all 9 authors...
Background Long-term survival (LTS) is uncommon for patients with pancreatic ductal adenocarcinoma (PDAC). We sought to identify factors that predict 10-year, LTS after resection of PDAC. Methods We identified all patients with PDAC who underwent resection at UCLA after 1990 and included all patients eligible for observed LTS (1/1/1990—12/31/2004). An independent pathologist reconfirmed the diagnosis of PDAC in patients with LTS. Logistic regression was used to predict LTS on the basis of patien...
16 CitationsSource
#1Daniel Ansari (Lund University)H-Index: 19
#2Bobby Tingstedt (Lund University)H-Index: 18
Last. Roland AnderssonH-Index: 54
view all 10 authors...
Pancreatic cancer is one of our most lethal malignancies. Despite substantial improvements in the survival rates for other major cancer forms, pancreatic cancer survival rates have remained relatively unchanged since the 1960s. Pancreatic cancer is usually detected at an advanced stage and most treatment regimens are ineffective, contributing to the poor overall prognosis. Herein, we review the current understanding of pancreatic cancer, focusing on central aspects of disease management from rad...
40 CitationsSource
#1Robert R. McWilliams (Mayo Clinic)H-Index: 39
Last. Albert B. Lowenfels (NYMC: New York Medical College)H-Index: 53
view all 18 authors...
Objectives While pancreatic cancer (PC) most often affects older adults, to date, there has been no comprehensive assessment of risk factors among PC patients younger than 60 years. Methods We defined early-onset PC (EOPC) and very-early-onset PC (VEOPC) as diagnosis of PC in patients younger than 60 and 45 years, respectively. We pooled data from 8 case-control studies, including 1954 patients with EOPC and 3278 age-and sex-matched control subjects. Logistic regression analysis was performed to...
13 CitationsSource
#1Xing Shugang (JLU: Jilin University)H-Index: 1
#2Yang Hongfa (JLU: Jilin University)H-Index: 1
Last. Li Wei (JLU: Jilin University)H-Index: 2
view all 7 authors...
PURPOSE: The prognostic value of SMAD4 in pancreatic cancer has been evaluated in several studies. However, the conclusions remain controversial. Therefore, we aimed to evaluate the association between SMAD4 expression and the outcome of pancreatic cancer patients by performing a meta-analysis. METHODS: We systematically searched for relevant studies evaluating the relationship between SMAD4 expression and the outcome of pancreatic cancer patients until May 2015. A meta-analysis was performed us...
18 CitationsSource
#1Matteo Piciucchi (Sapienza University of Rome)H-Index: 10
#2Gabriele Capurso (Sapienza University of Rome)H-Index: 37
Last. Gianfranco Delle Fave (Sapienza University of Rome)H-Index: 29
view all 15 authors...
Abstract Background About 10% of pancreatic cancer patients are aged ≤50 at diagnosis and defined as Early Onset Pancreatic Cancer (EOPC). There is limited information regarding risk factors for EOPC occurrence and their outcome. Aim To investigate risk factors, presentation features and outcome of EOPC patients. Methods Consecutive, histologically confirmed, pancreatic cancer patients enrolled. Data regarding environmental and genetic risk factors, clinical and pathological information, treatme...
10 CitationsSource
#1Lola Rahib (Pancreatic Cancer Action Network)H-Index: 6
#2Benjamin D. SmithH-Index: 43
Last. Lynn M. Matrisian (Pancreatic Cancer Action Network)H-Index: 7
view all 6 authors...
Cancer incidence and deaths in the United States were projected for the most common cancer types for the years 2020 and 2030 based on changing demographics and the average annual percentage changes in incidence and death rates. Breast, prostate, and lung cancers will remain the top cancer diagnoses throughout this time, but thyroid cancer will replace colorectal cancer as the fourth leading cancer diagnosis by 2030, and melanoma and uterine cancer will become the fifth and sixth most common canc...
1,624 CitationsSource
Cited By0
#1Ritu R. Singh (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
#2E. M. O' Reilly (Cornell University)H-Index: 45
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced stage, with systemic therapy being the mainstay of treatment. Survival continues to be limited, typically less than 1 year. The PDAC microenvironment is characterized by a paucity of malignant epithelial cells, abundant stroma with predominantly immunosuppressive T cells and myelosuppressive-type macrophages (M2), and hypovascularity. The current treatment options for metastatic PDAC are modified (m)FOLFIRINOX /FOLFIRI...
Background: The incidence of young patients with pancreatic cancer (PC) is on the rise, and there is a lack of models that could effectively predict their prognosis. The purpose of this study was to construct nomograms for predicting the overall survival (OS) and cancer-specific survival (CSS) of young patients with PC. Methods: PC patients younger than 50 years old from 2004 to 2015 in the Surveillance, Epidemiology, and End Results (SEER) database were selected and randomly divided into traini...
#1Hidetoshi Eguchi (Osaka University)H-Index: 45
#2Shogo Kobayashi (Osaka University)H-Index: 25
Last. Yuichiro Doki (Osaka University)H-Index: 61
view all 5 authors...